Lluis Soler

📢 EMA suspends #hydroxyprogesterone from the EU market. Patient demand for safer and effective alternatives! Aurisco has the solution! 👉Aurisco holds the only generic CEP for #Dydrogesterone 👉Auxiton® (Dydrogesterone) is approved and commercialized in China and available for licensing. 📧[email protected]📧 #EMAsuspends #patientsafety #aurisco Aurisco Pharmaceutical Co.,Ltd #17hydroxyprogesteronecaproate #17OHPC 17-hydroxyprogesterone caproate (17-OHPC) is a synthetic form of hydroxyprogesterone which naturally occurs in the body and is formed from progesterone. Progesterone is involved in preparing the endometrium (womb lining) for pregnancy and maintaining it during pregnancy. 17-OHPC is thought to attach to receptors (targets) on cells that normally are targeted by progesterone. This was expected to reduce the risk of pregnancy loss or premature labour in pregnant women and help treat certain infertility and gynaecological disorders related to a lack of progesterone. 17-OHPC is available as a solution for injection. Within the EU, the medicine is currently authorised in Austria, France, and Italy under the trade names #Proluton Depot, Progesterone Retard #Pharlon and #Lentogest.

17

It has been an honor to take part in the ΣΦΕΕ / SFEE - Σύνδεσμος Φαρμακευτικών Επιχειρήσεων Ελλάδος Summit panel on 'EU Pharma Legislation: How It Could Impact Access and Innovation'. Europe stands at a pivotal moment in its journey of innovation. The question ahead of us is clear: Will we be pioneers in the field of biotechnology, or will we be followers? The urgency for swifter regulatory processes and enhanced access to innovative treatments for our patients has never been greater. In a world where new technologies are rapidly emerging, revising European legislation is imperative. Together, we have the power to forge the path forward and redefine the future of innovation in Europe and contributing the increased global #Competitiveness of the EU Biotech sector. Let's unite and propel Europe to the forefront of global innovation! Special thank you to organizers and healthcare leaders for the excellent exchange: Olga Solomon, Head of Unit Medicines, DG SANTE, European Commission Stelios Kympouropoulos, MEP, Coordinator - Environment, Public Health and Food Safety Aris Angelis, Secretary General for Strategic Planning, Ministry of Health Michael Himonas, General Manager, SFEE Dimitrios Athanasiou MBA, President, Rare Disease Greece; BoD World Duchenne Organization; PCWP Member European Medicines Agency Vasiliki Angouridi, Health Editor, News4Health.gr / Euractiv.com #SFEE #SFEESummit2024 #EUPharmaLegislation #HealthcareInnovation #EUCompetitiveness #AccessToInnovation

159

9 comentarios

In order to assess whether #pharmaceutical manufacturers from EAEU countries face barriers to entry into the participant countries market, the Department of Antimonopoly Regulation (DAR) of the Eurasian Economic Commission is surveying representatives of the EAEU pharmaceutical industry.   According to the Methodology for Assessing the State of Competition, approved by the Council of the EAEU, barriers to entry into commodity market refer to the process of identifying the circumstances (actions) preventing a business entity from entering the market. Commodity entry barriers can take the form of administrative or economic restrictions, as well as restrictions imposed by market participants' behavior. The Commission's Antimonopoly Regulation Department is focused on assessing a set of factors and potentially harmful anti-competitive strategies that negatively affect medicines availability for consumers in Union countries. The survey results will be summarized in the Commission’s study on relevant topics and submitted to the EAEU bodies for consideration.  DAR invites drug manufacturers to fill out a form (enclosed to this post), and send it with a covering letter to the Commission staff email addresses: [email protected]; [email protected]. It is a great opportunity for market players to identify all emerging problems, especially potentially harmful anti-competitive strategies) #healthcare; #businessdevelopment; #marketaccess

8

📍At #Bio€quity Europe in San Sebastian, Spain investors gather to network, partner, and debate critical issues facing the biotech industry. @Giulia Vestri, Head of Business Development, will give a 🗨️ presentation to investors on behalf of @Azafaros. The presentation will be held in Room 6+7 on Monday, 📅 May 13 from 11:45 to 11:57 as part of the Endocrine and Metabolic track. Looking forward to seeing you there and connecting with investors! #Azafaros, #investors, #Start-ups, #Bio€quity, #Biocentury,

66

4 comentarios